Ad
Friday, 2 December 2016
Lilly's diabetes drug Jardiance cuts risk of cardiovascular death: FDA
(Reuters) - The U.S Food and Drug Administration said on Friday it had approved Eli Lilly and Co and Boehringer Ingelheim Pharmaceuticals Inc's drug, Jardiance, to reduce the risk of cardiovascular death in patients with type 2 diabetes.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment